UBS AM’s Soleno Therapeutics SLNO Stock Holding History

UBS AM’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-71,986	Closed	-$2.41M	–	3848
2026 Q1	$2.41M	Sell	71,986 -374	-0.5%	-$14.7K	﹤0.01%	1948
2025 Q4	$3.35M	Buy	72,360 +13,968	+24%	+$766K	﹤0.01%	1658
2025 Q3	$3.95M	Sell	58,392 -30,613	-34%	-$2.27M	﹤0.01%	1479
2025 Q2	$7.46M	Buy	89,005 +48,290	+119%	+$3.61M	﹤0.01%	1502
2025 Q1	$2.91M	Buy	40,715 +13,211	+48%	+$643K	﹤0.01%	1826
2024 Q4	$1.24M	Buy	27,504 +5,462	+25%	+$283K	﹤0.01%	2282
2024 Q3	$1.11M	Sell	22,042 -1,489	-6%	-$71.3K	﹤0.01%	2346
2024 Q2	$960K	Buy	23,531 +14,707	+167%	+$623K	﹤0.01%	2389
2024 Q1	$378K	Buy	+8,824	New	+$399K	﹤0.01%	2353

UBS AM's SLNO Position: Q2 2026 in Review

UBS AM sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 71,986 shares — an estimated $2.41M sold.

UBS AM first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $7.46M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

UBS AM reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
UBS AM sold 71,986 Soleno Therapeutics shares in Q2 2026, an estimated $2.41M.
UBS AM first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
UBS AM's Soleno Therapeutics position peaked at $7.46M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.